Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Straumann Holding AGXSWX:STMN +1.36%97 Intrinsic Value: Projected FCF is CHF37.20 as of Aug. 12, 2026, which is 100% below its 10-year median of 3.68. GuruFocus rates XSWX:STMN with a GF Score™ of 97/100 and a GF Value™ of CHF136.56 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 404 Medical Devices & Instruments companies, Straumann Holding AG ranks worse than 74.75% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
The historical rank and industry rank for Straumann Holding AG's Intrinsic Value: Projected FCF or its related term are showing as below:
XSWX:STMN'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 2.51 Med: 3.68 Max: 6.85
Current: 2.81
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Straumann Holding AG was 6.85. The lowest was 2.51. And the median was 3.68.
XSWX:STMN's Price-to-Projected-FCF is ranked worse than 74.75% of 404
companies
in the Medical Devices & Instruments industry
Industry Median: 1.495
vs XSWX:STMN: 2.81
Straumann Holding AG (XSWX:STMN) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Straumann Holding AG's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
104.35
/
37.201445799979
=
2.80
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Straumann Holding AG Intrinsic Value: Projected FCF Related Terms
Straumann Holding AG Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Straumann Holding AG's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Straumann Holding AG Intrinsic Value: Projected FCF Chart
XSWX:STMN vs ISRG, BDX, MDLN: Intrinsic Value: Projected FCF Comparison
For the Medical Instruments & Supplies subindustry, Straumann Holding AG's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Straumann Holding AG Price-to-Projected-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Straumann Holding AG's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Straumann Holding AG's Price-to-Projected-FCF falls into.
Straumann Holding AG Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of CHF37.20 mean?
Straumann Holding AG (XSWX:STMN) has a Intrinsic Value: Projected FCF of CHF37.20 as of Aug. 12, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Straumann Holding AG and its competitors. This is 911% above median its historical median of 3.68. Over the past decade, Straumann Holding AG's Intrinsic Value: Projected FCF has ranged from 2.51 to 6.85. According to the industry distribution chart, Straumann Holding AG ranks #302 out of 404 companies in the Medical Devices & Instruments industry, placing it in the top 74.8%.
Is Straumann Holding AG's Intrinsic Value: Projected FCF too high?
Straumann Holding AG's current Intrinsic Value: Projected FCF of CHF37.20 is 911% above median its 10-year median of 3.68. Over the past 10 years, this metric has ranged from a low of 2.51 to a high of 6.85. Based on the distribution chart, Straumann Holding AG ranks #302 out of 404 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Straumann Holding AG has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Straumann Holding AG's Intrinsic Value: Projected FCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Straumann Holding AG ranks #302 out of 404 companies for Intrinsic Value: Projected FCF. This places Straumann Holding AG in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.50. Historically, Straumann Holding AG's own Intrinsic Value: Projected FCF has ranged from 2.51 to 6.85 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Medical Devices & Instruments company?
The median Intrinsic Value: Projected FCF among Medical Devices & Instruments companies is 1.50, based on 404 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Straumann Holding AG and its competitors. For the Medical Devices & Instruments industry, the median Intrinsic Value: Projected FCF is 1.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Straumann Holding AG's current Intrinsic Value: Projected FCF is CHF37.20, which is 911% above median its own 10-year median of 3.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Straumann Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Straumann Holding AG (XSWX:STMN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF136.56, compared to a current price of CHF104.35 — trading 23.6% below its estimated fair value. The current Intrinsic Value: Projected FCF is CHF37.20, which is 911% above median its 10-year median of 3.68. Straumann Holding AG's overall GF Score™ is 97/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Straumann Holding AG (XSWX:STMN), the current Intrinsic Value: Projected FCF is CHF37.20 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Straumann Holding AG (XSWX:STMN) Overvalued in 2026?
Based on GuruFocus' analysis, Straumann Holding AG stock appears to be undervalued.
The current stock price of CHF104.35 is trading 23.6% below its estimated GF Value™ of CHF136.56.
GuruFocus considers Straumann Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:STMN:
Intrinsic Value: Projected FCF: CHF37.20 (911% above median its 10-year median of 3.68)
GF Value™: CHF136.56 vs. price of CHF104.35 (23.6% below fair value)
No single metric tells the full story. See the XSWX:STMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The firm's core products are dental implants, and it holds over one third of the CHF 6 billion global market. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 15% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands.
97GF Score
Get the complete analysis for XSWX:STMN
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:STMN has been successfully added to your 
